Maravai LifeSciences (NASDAQ:MRVI) Issues Earnings Results

Maravai LifeSciences (NASDAQ:MRVI) released its quarterly earnings data on Wednesday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.03, FiscalAI reports. The firm had revenue of $45.85 million during the quarter, compared to the consensus estimate of $43.56 million. Maravai LifeSciences had a negative return on equity of 12.23% and a negative net margin of 30.83%.

Here are the key takeaways from Maravai LifeSciences’ conference call:

• Q3 revenue rose 10% to $45.9 million, led by mRNA growth of 28% (GMP consumables +30%, discovery mRNA +27%). Cygnus grew 8%, marking its sixth consecutive quarter of year-over-year growth.
• Adjusted EBITDA improved by $16.6 million year over year to $5.8 million, and Maravai raised its 2026 revenue outlook to $212–$216 million and adjusted EBITDA outlook to $40–$42 million.
• Management cited a healthy mRNA pipeline and growing customer adoption: 10 discovery customers transitioned to clinical-stage GMP year to date, surpassing the company’s target of nine, and more than 180 customers are using ModTail.
• Management cautioned that GMP and CDMO orders are program-driven and can vary significantly by quarter; it expects GMP activity to skew toward the second half of 2027 and does not anticipate substantial 2027 GMP revenue from ModTail. Specialty chemistry revenue also declined 4% as large prior-year orders did not repeat.

Maravai LifeSciences Stock Up 7.8%

MRVI stock traded up $0.55 during trading on Friday, reaching $7.53. The stock had a trading volume of 1,364,314 shares, compared to its average volume of 2,476,949. The company has a quick ratio of 2.98, a current ratio of 4.05 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -17.50 and a beta of 0.61. Maravai LifeSciences has a one year low of $2.55 and a one year high of $9.42. The company’s 50 day moving average is $7.38 and its two-hundred day moving average is $5.31.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MRVI. Wells Fargo & Company increased their target price on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a report on Friday, August 7th. TD Cowen assumed coverage on shares of Maravai LifeSciences in a research note on Monday, October 5th. They set a “buy” rating and a $9.00 price target for the company. Wall Street Zen lowered shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. Finally, UBS Group raised their price objective on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $7.38.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.